A series of 1,6-dihydro-2-hydroxyethylamino-6-oxo-4-arylpyrimidine-5-carbonitriles 8a-i, and 4-amino-2-hydroxyethylamino-6-arylpyrimidine-5-carbonitriles 9a-i were prepared. Multicomponent reaction of araaldehyde 1a-i , S-methylisothiourea sulfate 2 with ethyl cyanoacetate 3 afforded 1,6-dihydro-2-methylthio-6-oxo-4-arylpyrimidine-5-carbonitriles 4a-i. Also, multicomponent reaction of 1, 2 with malononitrile 5 afforded 4-amino-2-methylthio-6-arylpyrimidine-5-carbonitriles 6a-i. Reaction of compounds 4a-i, and 6a-i with ethanolamine 7 under solvent free condition at 130-140 °C afforded 8a-i, and 9a-i respectively. The purity of the new compounds was checked by TLC and elucidation of their structures was confirmed by IR, 1 H-NMR, 13 C-NMR and HRMS spectrometry. Compounds were subjected to NCI in vitro assessment for their anticancer activity at a single dose of 10 µM of test compounds, Also, all of the tested compounds were in vitro assessment for their antibacterial and antifungal activities in a comparison to chloramphenicol and clotrimazole as reference antibacterial and antifungal drugs respectively. All the tested compounds showed varied anticancer activities ranging from weak to moderate activities. In the other hand, most of them showed moderate antibacterial activities without any antifungal activities.
INTRODUCTION
The chemistry of 2-aminopyrimidines has been attracting widespread attention over many decades. The popularity of these compounds is due to their a wide range of pharmacological activities such as antibacterial, (Siddiqui et al., 2007; Sreenivas et al.., 2012; Srinivas and Thakur, 2013) antifungal, (Sreenivas et al.., 2012; Srinivas and Thakur, 2013; Kachroo et al., 2014) antituberculosis, (Siddiqui et al., 2007; Kachroo et. al, 2014) antioxidant, (Kachroo et al., 2014; Mondal et al., 2010) antiviral, (Siddiqui et al., 2007; Fujiwara et al., 2008) antiprotozoal, (Scribner et al., 2007; Kumar et al., 2008) anticancer, (Akue-Gedu et al., 2009) analgesic, Gupta et al., 2011) and anti-inflammatory activities. (Kachroo et al., 2014; Bahekar and Shinde, 2003) In the same manner, 2-aminopyrimidines have been reported, or included as a part of many clinically active pharmaceutical drugs (Fig. 1) . In this manner, pyrimethamine as antiprotozoal, (Russel and Hitchings, 1951) sulfadiazine (Roblin and Winnek, 1940) and trimethoprim (Roth et al., 1987) as antibacterial, glymidine as antidiabetic, (Gutsche et al., 1964) minoxidil as antihypertension, (McCall et al., 1975) temelastine as antihistamine, (Alexander et al., 1956 ) and imatinib as antineoplastic. (Zimmermann et al., 1997) .
On the other hand, the polar functional 2-hydroxyethyamino is included as a part of many active pharmaceutical drugs ( Fig. 2) as in metronidazole as antiprotozoal, (Jacob et al., 1960) ethambutol as antituberculosis, (Wilkinson et al., 1962) perphenazine as antipsychotic, (Sherlock and Sperber, 1958) mitoxantrone (Zee-Cheng and Cheng, 1978) and olomoucine (Havlicek et al., 1997) as antineoplastic agents, and miglitol antidiabetic. (Yoshikuni et al., 1988) . Additionally, 2-hydroxyethylamino residue was chemically connected to variable organic formulations to elicit many desired biological activities as in palmitoyl ethanolamide as anti-inflammatory, (Lambert et al., 2002) 4-(2-hydroxyethylamino) coumarins as antitumor, (Angelova and Momekov, 2014) Nhydroxyethylglycolamides as antituberculosis. (Daryaee et al., 2009 ) Also the ethanolamine has antimicrobial, (Sandin et al., 1990) and antioxidant properties. (Sergeevna et al., 2013) . Supported by the aforementioned biological activities, the present study aimed at gathering the 2-aminopyrimidine derivatives and 2-hydroxyethylamino functional as 2-(2-hyroxyethylamino) pyrimidines and investigate their antimicrobial and anticancer properties aiming to development of a newly active agents.
MATERIALS and METHODS: Chemistry
Melting points were determined on an electrothermal melting point apparatus (Stuart Scientific Co.) and were uncorrected. Pre-coated silica gel plates (kieselgel 0.25 mm, 60G F254, Merck, Darmstadt, Germany) were used for TLC monitoring of reactions. The developing solvent systems of CHCl 3 /CH 3 OH (9:1 v/v) were used and the spots were detected at 254 nm wavelength using ultraviolet lamp (Spectroline, model CM-10, Seattle, USA). IR spectra (KBr discs) were recorded for compounds 8a-8e, 9b, 8d on a Shimadzu 435 spectrometer at the unit of Microanalysis, Cairo University, and the rest of the compounds were recorded on Thermoscientific, Nicolet-6700 FT-IR spectrometer at the Faculty of Pharmacy, Assiut University.
1 H-NMR and 13 C-NMR spectra of compounds 8a, 8c, 8g, 9b, 9c, and 9g were recorded using Varian Unity INOVA 400 MHz at university of Aberdeen, United Kingdom, and for the rest of the compounds on a Varian spectrometer or a Varian Mercury machine operating at Research School of Chemistry, Australian National University, Australia.
1 H-NMR operating at 400 MHz and 13 C-NMR operating at 100
MHz. Chemical shifts are expressed in δ-value (ppm) relative to DMSO-d 6 as internal standard,. 1 H NMR data are recorded as follows: chemical shift (δ) [multiplicity, coupling constant (s) J (Hz) and relative integral, where multiplicity is defined as: s= singlet; d= doublet; t= triplet; q= quartet; m= multiplet or combinations of the above.
High resolution mass spectrometric data for 8a, 8c, 8g, 9b, 9c, and 9g compounds were obtained using the EPSRC mass spectrometry Centre in Swansea and Thermo Instruments MS system (LTQ XL/LTQ Orbitrap Discovery) coupled to a Thermo Instruments HPLC system (Accela PDA detector, Accela PDA autosampler and Pump) at university of Aberdeen, UK. High resolution MS data for the rest of compounds were obtained using a VG Fisons AutoSpec mass spectrometer (electron impact (EI) mass spectra), high-resolution electrospray (ESI) mass spectra were obtained on a VG Quattro II triple-quadrupole MS instrument operating in positive ionization mode at Research School of Chemistry, Australian National University, Australia. Compounds yields given are those of crude products. Ethyl cyanooacetate was purchased from s.d.fine limited Co., malononitrile was purchased from Acros Co., Compounds 5a-i (Rong et al., 2013; Hussein et al., 2011; Agarwal et al., 2002) and 6a-i (Kumar, 2008; Rong et al., 2012; Rostamizadeh and Nojavan, 2014) were prepared according to reported methods. (Rong et al., 2013; Rong et al., 2012) All solvents were obtained from commercial suppliers and used without further purification.
General procedure for synthesis of 2-(2-hydroxyethylamino)-6-oxo(or 4-amino)-pyrimidine-5-carbonitriles (8a-i) and (9a-i) 2-Methylthiopyrimidines 5a-i or 6a-i (5.0 mmol) were heated in oil bath under solvent free condition with 2.5 ml of ethanolamine 7 at 130-140 °C for 3 h. The reaction mixture was cooled, diluted with 50 ml isopropyl alcohol and set aside in refrigerator to precipitate. The formed precipitate was filtered, washed with cold isopropyl alcohol, dried and crystallized from isopropyl alcohol. 
1,6-dihydro-2-(2-hydroxyethylamino)-4-(naphthalen-1-yl)-6-oxopyrimidine-5-carbonitrile 8h
Yield, 68%; M.P., 242-44ºC; IR (KBr) 134.95, 133.07, 129.87, 129.62, 128.27, 126.77, 126,30, 126.14, 125.17, 125.05 
1,6-dihydro-4-(furan-2-yl)-2-(2-hydroxyethylamino)-6-oxopyrimidine-5-carbonitrile 8i
Yield, 65%, M. 
Biology

Anticancer screening
The methodology of the NCI anticancer screening has been described previously.
(http://www.dtp.nci.nih.gov) Briefly, the primary anticancer assay was performed at approximately 60 human tumor cell lines panel derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda. They include nine tumor subpanels namely; leukaemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancer cells. The data reported as mean graph of the percent growth of the treated cells, and presented as percentage growth inhibition (GI %).
Tested compounds were added to the culture at a single concentration (10 µM) and the cultures were incubated for 48 h. End point determinations were made with a protein binding dye, SRB. Results for each tested compound were reported as the percent of growth of the treated cells when compared to the untreated control cells. The percentage growth was evaluated spectrophotometrically versus controls not treated with test agents.
Antibacterial activity
Eighteen compounds 8a-g, and 9a-g were tested for their antibacterial activity in vitro, in comparison with chloramphenicol as a reference drug using the standard agar cup diffusion method (Hussein et al., 2016) To prepare inocula, bacterial strains were individually cultured for 24 h in 100 ml conical flasks containing 30 ml nutrient broth medium. Bioassay was done in 10 cm sterile plastic about 1m of bacterial suspension was mixed with 15 ml Nutrient agar medium and poured in Petri plates. After solidification of the media, cups were cut in the solidified agar (4 cups/plate) using sterile cork borer. Tested compounds dissolved in dimethylsulfoxide (DMSO) at 100 µmol/ML were pipetted in the cups (20 ul/ cavity). Cultures were then incubated at 28 ± 2 °C for 48 h. The diameter (in mm) of inhibition zone was recorded.
The test compounds giving positive results were diluted with DMSO to prepare a series of descending concentrations and were similarly assayed as mentioned before and the least concentration which inhibited bacterial growth was recorded as the MIC.
Antifungal activity
All the newly synthesized compounds 8a-g, and 9a-g were tested for their antifungal activity in vitro, in comparison with cloterimazole as a reference drug using the standard agar cup diffusion method (Hussein et al., 2016) To prepare inocula, Fungi were grown for 7 days in 100 ml conical flasks containing 30 ml sabouraud`s dextrose broth. Bioassay was done in 10 cm sterile Petri plates in which 1 ml of fungal suspension and 15 ml sabouraud`s dextrose agar medium were mixed and poured. After solidification of the media, cups were cut in the solidified agar (4 cups/plate) using sterile cork borer. Tested compounds dissolved in dimethylsulfoxide (DMSO) at 100 μmol/ml were pipetted in the cups (20 μl/cavity). Cultures were then incubated at 28°C up to 7 days. Results were read as the diameter (in mm) of inhibition zone.
RESULTS and DISCUSSION: Chemistry
1,6-dihydro-2-(2-hydroxyethylamino)-6-oxo-4-arylpyrimidine-5-carbonitriles 8a-i were prepared according to Scheme 1. The synthones 1,6-dihydro-2-methylthio-6-oxo-4-arylpyrimidine-5-carbonitriles 4a-i were prepared by multicomponent reaction of araldehydes 1a-i, S-methylisothiourea sulfate 2 and ethyl cyanoacetate 3 by reflux in ethanol containing sodium hydroxide. (Rong et al., 2013) Heating of compounds 4a-i with ethanolamine 7 under solvent free condition at 130-140 °C for 3 hour afforded 1,6-dihydro-2-(2-hydroxyethylamino)-6-oxo-4-arylpyrimidine-5-carbonitriles 8a-i. This is a simple green with high yield and easily purified condition method.
IR spectra of compounds 8a-i showed broad bands at 3400-3200 cm -1 (OH, 2NH) and a characteristic bands at 2200 cm -1 (C≡N), 1667 cm -1 (C=O ), 1575 cm -1 (C=N). 1 H-NMR spectra of these compounds showed the appearance of a broad signal for the amidic NH protons at δ 11.60-11.3, and the other amino signal appeared incorporated with aromatic proton at about δ 7.2. A characteristic broad signal appeared at δ 5.0 assigned for OH proton. Also, appearance of the aliphatic side chain proton signals at δ 3.55-3.33 as triplet or incorporate together as a multiplet.
13 C NMR spectra for this series showed characteristic two peaks in about δ 43 and δ 59 corresponding to aliphatic side chain carbon atoms, peaks appeared at δ 75 -90 assigned for pyrimidine C5C≡N carbon atom. Also, a characteristic peak at δ 117 assigned for C≡N, peaks between δ 145-112 assigned for aromatic carbons. Additionally, peaks at δ 155-160, 160-164, and 169-171 assigned for Pyrimidine C2, Pyrimidine C6(CO) and pyrimidine C4 respectively. 4-amino-2-(2-hydroxyethylamino)-6-arylpyrimidine-5-carbonitriles 9a-i were prepared according to Schemes 2.
Again, the other synthones 4-amino-2-methylthio-6-arylpyrimidine-5-carbonitriles 6a-i were prepared by multicomponent reaction of 1, 2 with malononitrile 5 by refluxing in ethanol containing sodium hydroxide. (Rong et al., 2012) In the same way, heating of compounds 6a-i with ethanolamine 7 under solvent free condition at 130-140 °C for 3 hour afforded 4-amino-2-(2-hydroxyethylamino)-6-arylpyrimidine-5-carbonitriles 9a-i IR spectra of compounds 9a-i showed broad bands at 3400, 3200, 3120 cm -1 (OH, NH 2 , NH) and a characteristic bands at 2200 cm -1 C≡N, and 1660-1600 cm -1 which assigned for C=N.
1 H-NMR spectra of these compounds showed the appearance of a broad signal at δ 7.50 assigned for the NH proton. Other NH 2 signals appeared as a broad single band or incorporated with aromatic proton signals at δ 7.3-7.0. Also, appearance of characteristic broad signal at δ 5.0 assigned for OH proton. Again, the presence of aliphatic side chain proton signals at δ 3.55-3.33 as triplet or incorporate together as a multiplet.
13 C NMR spectra for this series showed characteristic two peaks in the region δ 43 and δ 60 corresponding to aliphatic side chain carbon atoms, peaks at δ 72 -80 for pyrimidine C5C≡N carbon atom. Also, a characteristic peak appeared at δ 117 assigned for C≡N, peaks between δ 112-155 assigned for aromatic carbons. Additionally, peaks at δ 155-160, 160-164, and 169-171 assigned for Pyrimidine C2, Pyrimidine C4(C4NH 2 ), and Pyrimidine C6 respectively.
Biology
Anticancer activity
Eleven newly synthesized compounds 8a, 8c, 8d, 8f, 8g, 8h, 8i, 9a, 9d , 9e, and 9f were selected by the National Cancer Institute (NCI) according to the protocol of the Drug Evaluation Branch of the National Cancer Institute, Bethesda, USA for in vitro anticancer screening. (NCI methodology, http://www.dtp.nci.nih.gov) A single dose (10 μM) of the test compounds was used in the full NCI 60 cell lines panel assay which includes nine tumor subpanels namely; leukaemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancer cells. The data reported as mean graph of the percent growth of the treated cells, and presented as percentage growth inhibition (GI %). The obtained results of the tested 2-(2-hyroxyethylamino)pyrimidine derivatives are shown in Table 1 .
The obtained results of tested compounds, 2-(2-hyroxyethylamino)-6-oxopyrimidines series 8 showed variable sensitivity profiles against most of the tested compounds ( Table 1) . Regarding the activity towards individual cell lines, the most sensitive cancer cell line to series 8a-i were CNS cancer (SNB-75) with moderate activity of compounds 8a (4-phenyl derivatives), 8c (4-p-chlorophenyl derivatives), and 8g (4-(thiophen-2-yl derivative) with GI % 23.03, 19.02, and 19.39 respectively; renal cancer (UO-31) with moderate activity of compounds 8a (4-phenyl derivatives), and 8c (4-p-chlorophenyl derivatives) with GI % 23.65, and 25.61 respectively. Also, compound 8g(4-thiophen-2-yl derivative) showed moderate activity against leukemia (MOLT-4) with GI % 21.37; and compound 8h (4-(1-naphthyl) derivative) showed moderate activity against non-small cell lung cancer (NCI-H522) GI % 22.59. The most active compounds for this series were 8a, 8c.
On the other hand, 4-amino-2-(2-hyroxyethylamino)-pyrimidine analogues series 9 also showed variable sensitivity profiles against most of the tested compounds ( Table 1) . The most sensitive cancer cell line by this series 9 were non-small cell lung cancer (A549/ATCC) with moderate activity of compound 9d (6-p-fluorophenyl derivatives) with GI % 28.21; (Hop-920 with moderate activity of compounds 9d (6-(pfluorophenyl derivatives), and 9f (6-pmethoxyphenyl derivatives) with GI % 24.09, and 28.91 respectively; NCI-H226 with moderate activity to compounds 9d (6-(pfluorophenyl derivatives), and 9f (6-(pmethoxyphenyl derivatives) with GI % 22.94, and 19.63 respectively; (NCI-H522) with moderate activity of compound 9e (6-p-tolyl derivatives) with GI % 20.62; and CNS cancer (SNB-75) with moderate activity of compound 9a (6-phenyl derivatives), and 9d (6-p-fluorophenyl derivatives) with GI % 19.23, and 21.79 respectively; renal cancer (A498) with moderate activity of compound 9e (6-p-tolyl derivatives) with GI % 22.23; and breast cancer (T-47D) with moderate activity of compound 9d (6-p-fluorophenyl derivatives) with GI % 20.28; the most active compounds for this series were compounds 9d, and 9f.
Antibacterial activity
Results of the antibacterial activity for 6-oxo-2-hydroxyethylpyrimidines 8a-i, revealed that at concentration of 100 µmol/mL, most of the test compounds show moderate activity against most of the used bacterial strains ( Table 2 ). The most sensitive strain for the compounds 8a-i were Staph. aureus and E. coli and the least sensitive strain was Ps. aeruginosa. The activities of tested compounds ranging 43-55% to the activities of the reference drug. 8a  8c  8d  8f  8g  8h  8i  9a  9d  9e  9f  Leukemia  CCRF-CEM  -----------HL-60(TB) - 11.66 
11.41 15.10 11.41 14.99
Renal Cancer 
The most active compounds for these series were compounds 8d (4-p-fluorophenyl derivatives) which is active against all used organisms and it has 50, 50, 43, 55, and 45% activity of the reference drug on Staph. aureus, B. cereus, E. Coli, Ps aeruginosa, and S. marcescens, respectively. Compounds having 4-hetero or 4-bulky aryl moieties 8g (thiophen-2-yl), 8h (1-naphthyl), or 8i (2-furyl) were completely inactive against all used organisms. Additionally, the MICs for the tested compounds of this series ranging between 50 and 100 µmol/mL which is weakly active in comparison to reference drug chloramphenicol ranging between 3 and 6.5 µmol/mL, and the most effective tested compounds of these series, were compounds 8c (4-p-chlororophenyl derivatives), and 8d (4-p-fluorophenyl derivatives) that have MICs 50 µmol/mL against Staph. aureus.
On other hand, the antibacterial activity for 4-amino-2-hydroxyethylpyrimidines 9a-i, revealed that at concentration of 100 µmol/mL most of test compounds show moderate activity against most of the used organisms ( Table 2 ). The ISSN 1110-5089 Vol 25, Issue 2 pp 77-92 89 most sensitive strains for these compounds 9a-i were Staph. aureus, E. coli, and Ps aeruginosa, and least sensitive strains was S. marcescens. The activities of the tested compounds ranging 43-55% to the activities of the reference drug. The most active compound for these series was compound 9a (6-phenyl derivatives) which is active against all used organisms and it has 40, 50, 43, 55, and 36% activity of the reference drug on Staph. aureus, B. cereus, E. Coli, Ps aeruginosa, and S. marcescens, respectivly. Again, compounds having 6-hetero or 6-bulky aryl moieties 9g (thiophen-2-yl), 9h (1-naphthyl), or 9i (2-furyl) were completely inactive against all used organisms. In addition, the MICs for the tested compounds of this series ranging between 50 and 100 µmol/mL which is weakly active in comparison to reference drug ranging between 3 and 6.5 µmol/mL, and the most effective tested compounds of these series, were compounds 9a (6-phenyl derivatives), 9c (6-p-chlororophenyl derivatives) that have MICs 50 µmol/mL against the Staph. aureus, and B. cereus respectively. Also, compound 9e (6-p-tolyl derivatives) that have MICs 50 µmol/mL against the B. cereus, E. colli, and Ps aeruginosa. Table 2 . Antibacterial activity of compounds 8a-i, 9a-i and chloramphenicol (inhibition zone in mm at100 µmol/ml) and MICs given in brackets (µmol/ml).
No.
Staphylococcus aureus 
Antifungal activity
The results showed that none of the tested compounds showed any activity against all of the used fungi strains.
CONCLUSION:
New two series of 1,6-dihydro-2-(2-hydroxyethylamino)-6-oxo-4-arylpyrimidine-5-carbonitriles 8a-i, and 4-amino-2-(2-hydroxyethylamino)-6-arylpyrimidine-5-carbonitriles 9a-i were synthesized for evaluation as anticancer and antimicrobial activities. Structure-activity data acquired and biological studies showed that, regarding anticancer screening i) all compounds of the two series showed varied anticancer activities ranging from weak to moderate activities; ii) in series 8, compounds having 4-phenyl (8a), and 4-p-chlorophenyl (8c) were the most active compounds against CNS cancer iii) regarding series 9, compounds having 6-p-fluorophenyl (9d), and 6-p-methoxyphenyl (9f) were the most active compounds of this series, 9d showed moderate activity against non-small cell lung cancer (A549/ATCC, Hop-92, NCI-H226), CNS cancer (SNB-75), and breast cancer (T-47D) with GI % 28.21, 24.09, 22.94, 21.79, and 20.28 respectively; 9f showed moderate activity against non-small cell lung cancer (Hop-92, NCI-H226), and renal cancer (A498) with GI % 28.91, 19.63, and 22.23 respectively; iv) the sensitivity of cancer cell lines toward the synthesized two new series was pounced in 4-amino-2-(2-hydroxyethylamino)-6-arylpyrimidines 9a-i more than 4-2-(2-hydroxyethylamino)-6-oxoarylpyrimidines 8a-i.
Regarding antimicrobial screening: i) Most of the tested compounds of the two series showed moderate activity against most of the used organisms at concentration of 100 µmol/mL. ii) The most sensitive strain for the two tested series were Staph. aureus, and E. colli. iii) The sensitivity of Ps aeruginosa was increased to series 9 (4-aminopyrimidines) more than series 8 (6-oxopyrimidines) but in case of S. marcescens the sensitivity was increased to series 8 more than series 9. iv) The most active compound of series 8 was 8d (4-p-fluorophenyl derivatives) which was active against all used organism and has MIC 50 µmol/mL against the Staph aureus, and the most active compound of series 9 was 9a (6-phenyl derivatives) which was active against all used organism and has MIC 50 µmol/mL against Staph aureus. v) Compounds having hetero or bulky aryl moieties in both series (8g, 9g, 8h, 9h, 8i, or 9i) were completely inactive against all used organisms. vi) Non of the test compounds showed any activity against all of the used fungi strains at a concentration of 100 µmol/mL.
